GSK Announced Headline Results From FIRST-ENGOT-OV44 Phase 3 Trial Of Zejula (Niraparib) And Jemperli (Dostarlimab) In First Line Advanced Ovarian Cancer, The Trial Met Its Primary Endpoint Of Progression-free Survival, The Key Secondary Endpoint Of...

Benzinga · Dec 20 17:01

GSK Announced Headline Results From FIRST-ENGOT-OV44 Phase 3 Trial Of Zejula (Niraparib) And Jemperli (Dostarlimab) In First Line Advanced Ovarian Cancer, The Trial Met Its Primary Endpoint Of Progression-free Survival, The Key Secondary Endpoint Of Overall Survival Did Not Meet Statistical Significance

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

GSK Announced Headline Results From FIRST-ENGOT-OV44 Phase 3 Trial Of Zejula (Niraparib) And Jemperli (Dostarlimab) In First Line Advanced Ovarian Cancer, The Trial Met Its Primary Endpoint Of Progression-free Survival, The Key Secondary Endpoint Of...

Risk Disclaimer